Chairman & Chief Executive Officer Dr. Robin Lin
/
    Education :
    • Ph.D., Biochemistry
    • Institute of Biochemistry, National Chung Hsing University

    Areas of Expertise :
    • Pharmaceutical Dosage Form Development
    • Strategic Planning for Innovative Drug R&D
    • Prescription Drug Marketing & Medication-Use Analysis

    Professional Summary :

        Dr. Robin Lin has extensive experience in pharmaceutical marketing and the biotechnology industry, previously serving at Mitsubishi Tanabe Pharma and innovative drug development companies. Dr. Lin has strong practical expertise in the prescription drug market and comprehensive capabilities in new drug development integration.

        Dr. Lin has led multiple preclinical development programs for innovative drug candidates and is highly skilled in integrating technology, regulatory strategies, and capital market considerations to ensure the effective execution of R&D projects. With deep insight into the biotechnology ecosystem and market trends, Dr. Lin continues to guide Ail Biotech in advancing 505(b)(2) innovative drug development and clinical applications.

        Currently, Dr. Lin is focused on expanding the company’s pipeline into therapeutic areas with unmet medical needs, aiming to create greater value and more treatment options for patients.
Vice General Manager Dr. Jay Hsieh
/
    Profile :
        Dr. Hsieh holds a Ph.D. in Pharmaceutical Chemistry from China Medical University. He previously worked as a practicing pharmacist at ophthalmology clinics and Chang Gung Memorial Hospital, gaining extensive clinical experience.
        Dr. Hsieh served as the principal investigator or co-principal investigator in a total of 47 research projects under the TFDA, including the Bioavailability and Bioequivalence Research Program and the Rare Diseases Drugs Annual Report Research Program. He has amassed extensive experience in drug development and quality control.
        From Dr. Hsieh transitioned into the biotechnical industry, he leveraged his experience to lead the license-in projects from NHRI, DCB, and ITRI, both in the past and present, significantly enhancing the company's R&D efficiency and corporate value.
R&D Director Dr. Tsung-Min Hsu
/
    Education：
    • Postdoctoral Research, University of Utah, USA
    • Ph.D. in Pharmaceutics, University of Utah, USA

    Areas of Expertise：
    • Drug Delivery Development
    • Strategic Planning for Innovative Drug R&D
    • Prescription Drug Marketing & Medication-Use Analysis

    Professional Summary：

        Dr. Tsung-Min Hsu earned his Ph.D. in Pharmaceutics from the University of Utah and later completed his postdoctoral research at the same institution. With over 30 years of extensive experience in the field of drug delivery systems, he has developed deep expertise in drug delivery and has been granted more than 20 invention patents.

        Dr. Hsu has served in multiple internationally renowned pharmaceutical companies and played pivotal roles in innovative drug development. Between 1990 and 1992, he worked as an R&D Team Leader at Berlex Pharmaceutical Inc., where he successfully developed an oral gel product produced through bioengineering technology, designed to enhance oral mucosal recovery for cancer patients.

        From 1992 to 1994, Dr. Hsu joined Cygnus Inc. as a Senior Research Scientist, where he led the development of the well-known Ortho-Evra® seven-day contraceptive patch, which was successfully commercialized.

        He later served as Vice President of R&D at Dermatreads Inc. (1999–2008), where he pioneered breakthrough technologies enabling transdermal delivery of large-molecule peptide drugs. During this period, he also successfully transferred the transdermal patch formulation technology for Paliperidone, a medication used for schizophrenia, to Teikoku Pharma in Japan—demonstrating strong capabilities in technology transfer and commercialization.

        Between 2008 and 2013, Dr. Hsu was the Vice President of R&D at D3forMe Inc., where he spearheaded the development of a Vitamin D3 transdermal patch, further showcasing his innovative achievements in drug delivery technology.

        Dr. Hsu's extensive industry experience and innovative research outputs not only highlight his technical expertise in drug delivery systems but also reflect his outstanding ability to advance and commercialize breakthrough pharmaceutical technologies.
Chief Financial Officer Jeff Lin
/
    Education :
    • Master's degree in Accounting and Finance, University of Southampton, England, UK

    Profile :
        CFO Lin previously worked at KPMG Taiwan and held key positions in the finance and accounting departments of several listed companies, including Pou Chen Corporation, HEP Tech Co., and Johnson Health Tech. His areas of expertise include financial statement analysis, cash flow planning, internal controls, and cross-departmental coordination.
        During his tenure at HEP Tech Co., he assisted the company in successfully completing its OTC listing application in Taiwan. He was responsible for group-level cash planning and management, as well as coordinating the financial affairs of overseas subsidiaries to ensure smooth international operations. In addition, CFO Lin participated in R&D tax credit applications and communications with the Industrial Development Bureau, helping the company reduce tax-related costs and enhance competitiveness.

        With his strong financial background and extensive international experience, CFO Lin provides a solid foundation for the company's financial strategy and long-term stable development—whether in financial analysis, cash flow planning, or cross-border collaboration.